Pfizer (PFE) Accounts Payables (2009 - 2026)
Pfizer (PFE) posted quarterly Accounts Payables of $4.5 billion for Q1 2026, down 14.01% year-over-year from $5.2 billion in Q1 2025, and down 14.01% quarter-over-quarter from $5.2 billion in Q4 2025.
Pfizer (PFE) Accounts Payables (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Accounts Payables for 18 consecutive years, with $4.5 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables fell 14.01% year-over-year to $4.5 billion; the TTM figure through Mar 2026 stood at $4.5 billion (down 14.01% YoY), while the FY2025 annual figure was $5.2 billion, down 6.98% from the prior year.
- Accounts Payables retreated to $4.5 billion in Q1 2026 per PFE's latest filing, from $5.2 billion in the prior quarter.
- Across five years, Accounts Payables topped out at $6.8 billion in Q4 2022 and bottomed at $4.5 billion in Q1 2026.
- Historically, Accounts Payables has averaged $5.6 billion across 5 years, with a median of $5.5 billion in 2022.
- Annual changes were most pronounced in 2022 — Accounts Payables surged 43.47% — and 2024, when it declined 16.05%.
- Pfizer's Accounts Payables stood at $6.8 billion in 2022, then dropped by 1.45% to $6.7 billion in 2023, then slipped by 16.05% to $5.6 billion in 2024, then dropped by 6.98% to $5.2 billion in 2025, then slipped by 14.01% to $4.5 billion in 2026.
- Business Quant data shows PFE's Accounts Payables at $4.5 billion in Q1 2026, $5.2 billion in Q4 2025, and $5.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 9.22 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 33.30 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 3.83 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 4.26 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 22.89 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 2.87 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 674.00 Mn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 4.58 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -19.24 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 8.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 4.58 Bn |
| Mar 29, 2026 | 4.51 Bn |
| Dec 31, 2025 | 5.24 Bn |
| Sep 28, 2025 | 5.02 Bn |
| Jun 29, 2025 | 5.17 Bn |
| Mar 30, 2025 | 5.24 Bn |
| Dec 31, 2024 | 5.63 Bn |
| Sep 29, 2024 | 5.31 Bn |
| Jun 30, 2024 | 5.11 Bn |
| Mar 31, 2024 | 5.59 Bn |
| Dec 31, 2023 | 6.71 Bn |
| Jul 2, 2023 | 6.08 Bn |
| Apr 2, 2023 | 6.12 Bn |
| Dec 31, 2022 | 6.81 Bn |
| Jul 3, 2022 | 6.21 Bn |
| Apr 3, 2022 | 5.51 Bn |
| Dec 31, 2021 | 5.58 Bn |
| Oct 3, 2021 | 4.70 Bn |
| Jul 4, 2021 | 4.33 Bn |
| Apr 4, 2021 | 4.06 Bn |